内容紹介
Summary
Healthcare economics concerns with the way in which to distribute and allocate scarce resources that result in maximized outcome. When the expenditure on cancer medicine was examined using the macro data open to the public, it was found to have increased in parallel with the National Medical Care Expenditure. More specifically, the growth rates of the two showed a similar trend in the five years from 2011 to 2015. However, when looked more closely by excluding the patient share and separating the care settings, the result was different. The expenditure in outpatient care displayed a significant increase, implying the influence of chemotherapy shifting to take place more in the outpatient setting. Current discussion on introducing the concept of cost effectiveness into the fee schedule scheme should be based on multidimensional consideration.
要旨
医療経済では,「稀少な資源を何にどう配分すれば最も効率的か」が問題となる。がんの医療費の伸び率について既存のマクロデータを使ってその実態を観察したところ,全体の医療費の伸び率とパラレルな関係があることが判明した。しかしその一方で,外来と入院に分けて医療給付費レベルで部位別に分析すると様相は一変した。これは外来シフトが著しい化学療法,特に高額薬剤が関係していると考えられる。そこで最近話題となっている費用対効果評価においても,一定の技術革新も考慮に入れて多面的な検討が求められる。
目次
Healthcare economics concerns with the way in which to distribute and allocate scarce resources that result in maximized outcome. When the expenditure on cancer medicine was examined using the macro data open to the public, it was found to have increased in parallel with the National Medical Care Expenditure. More specifically, the growth rates of the two showed a similar trend in the five years from 2011 to 2015. However, when looked more closely by excluding the patient share and separating the care settings, the result was different. The expenditure in outpatient care displayed a significant increase, implying the influence of chemotherapy shifting to take place more in the outpatient setting. Current discussion on introducing the concept of cost effectiveness into the fee schedule scheme should be based on multidimensional consideration.
要旨
医療経済では,「稀少な資源を何にどう配分すれば最も効率的か」が問題となる。がんの医療費の伸び率について既存のマクロデータを使ってその実態を観察したところ,全体の医療費の伸び率とパラレルな関係があることが判明した。しかしその一方で,外来と入院に分けて医療給付費レベルで部位別に分析すると様相は一変した。これは外来シフトが著しい化学療法,特に高額薬剤が関係していると考えられる。そこで最近話題となっている費用対効果評価においても,一定の技術革新も考慮に入れて多面的な検討が求められる。